LEO Pharma has closed its acquisition of dersimelagon from Tanabe Pharma after the FDA accepted the drug's NDA for filing and granted Priority Review, with a PDUFA date expected by the end of February 2027.
|Articles|August 8, 2018
- Dermatology Times, August 2019 (Vol. 39, No. 8)
- Volume 39
- Issue No. 8
Analysis shows nurses are overworked
Author(s)Dermatology Times Staff
Advertisement
Hawaii has the most overworked RN workforce, according to a report by Medicare Health Plann issued in June.
Other states with an overworked nursing workforce include --- in this order --- Utah, Wisconsin, Wyoming, District of Columbia, Washington, North Carolina, Oregon, Nevada and New Hampshire.
The report is based on an analysis of data from the U.S. Census Bureau compared to FBI crime data and data from the Kaiser Family Foundation that included the total number of healthcare professionals for each state.
This data was used to determine the number of physicians and nurses per every 1,000 people. States with higher person to nurse ratios, were considered states in which nurses were overworked.
Articles in this issue
about 8 years ago
Communication in the era of patient-centered careabout 8 years ago
Comprehensive psoriasis managementabout 8 years ago
Dermatology training for nurses and PAsabout 8 years ago
Is it time to regulate probiotics in cosmetics?about 8 years ago
11 steps to improving doctor-patient communicationabout 8 years ago
Language used in medical records can stigmatize patients for yearsabout 8 years ago
EC moves forward with new PsA treatmentabout 8 years ago
Make patient-centered work in practiceabout 8 years ago
New AAD cSCC treatment guidelinesabout 8 years ago
Emotional burden of skin conditions may be rooted in physiologyAdvertisement
Related to this article
Sol-Gel Technologies has completed patient follow-up in its pivotal phase 3 trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, with top-line results expected in late November 2026.
Two small clinical studies evaluated skincare and dermabrasion for changes in skin quality among individuals taking medical weight loss medications.
Two-year POETYK PsA-2 data showed sustained ACR and minimal disease activity responses with deucravacitinib and no new safety signals.
Faculty from the Cutaneous Oncology Workshop answer practical questions spanning skin cancer prevention, diagnosis, treatment, and follow-up.
Two new Neutrogena facial sunscreens incorporate bemotrizinol, the first new sunscreen active ingredient added to the US OTC monograph in decades.
Longer treatment duration was independently associated with VASI improvement, while publicly insured patients experienced higher topical JAK inhibitor denial rates.
Though convenient, SPF-infused cosmetics rarely deliver their labeled protection level in real-world use, underscoring the continued need for a dedicated broad-spectrum sunscreen as the foundation of any routine.
Advertisement
Advertisement
Trending on Dermatology Times
1
Neutrogena Launches New Sunscreens With Newly Permitted UV Filter Bemotrizinol
2
Two-Year POETYK PsA-2 Data Show Durable Deucravacitinib Responses in Psoriatic Arthritis
3
Longer Topical JAK Inhibitor Treatment Linked to Vitiligo Improvement in Real-World Study
4
Sun Protection in Beauty Routines: Is SPF Makeup Enough?
5